Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia

Cellular Immunology

Volumn 227, Issue 1, 2004, Pages 38-50

  Bae, Jooeun ^a   Martinson, Jeffrey A ^a   Klingemann, Hans G ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; CD33; Cytotoxic T lymphocytes; Immunotherapy; Peptide

Indexed keywords

ALANYLISOLEUCYLISOLEUCYLSERYLGLYCYLASPARTYLSERYLPROLYLVALINE; CD33 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; PEPTIDE; TYROSYLISOLEUCYLISOLEUCYLSERYLGLYCYLASPARTYLSERYLPROLYLVALINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOGENICITY; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ACUTE DISEASE; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; LEUKEMIA, MYELOID; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 1642346525     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellimm.2004.01.002     Document Type: Article

References (78)

1. Billiau A., Fevery S., Rutgeerts O., Landuyt W., Waer M. Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants. Blood. 100:2002;1894-1902.
2. Kruse C.A., Visonneau S., Kleinschmidt-DeMasters B.K., Gup C.J., Gomez G.G., Paul D.B., Santoli D. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy. Cancer Res. 60:2002;5731-5739.
3. Zeis M., Uharek L., Glass B., Vosskotter W., Dreger P., Schmitz N., Steinmann J. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation. Exp. Hematol. 26:1998;1068-1073.
4. Falkenburg J.H., Wafelman A.R., Joosten P., Smit W.M., van Bergen C.A., Bongaerts R., Lurvink E., van der Hoorn M., Kluck P., Landegent J.E., Kluin-Nelemans H.C., Fibbe W.E., Willemze R. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood. 94:1999;1201-1208.
5. Molldrem J., Lee P., Wang C. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6:2000;1018-1023.
6. + cytotoxic T lymphocyte clone specific for WT1 peptide. Blood. 95:2000;286-293.
7. Andrews R.G., Torok-Storb B., Bernstein I.D. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood. 62:1983;124-132.
8. Simmon D., Seed B. Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells. J. Immunol. 141:1988;2797-2802.
9. Robertson M.J., Soiffer R.J., Freedman A.S., Rabinowe S.L., Anderson K.C., Ervin T.J., Murray C., Dear K., Griffin J.D., Nadler L.M. Human bone marrow depleted of CD33-positive cells mediate delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood. 79:1992;2229-2236.
10. Sievers E.L., Larson R.A., Stadtmauer E.A., Estey E., Lowenberg B., Dombret H., Karanes C., Theobald M., Bennett J.M., Sherman M.L., Berger M.S., Eten C.B., Loken M.R., van Dongen J.J., Bernstein I.D., Appelbaum F.R. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19:2001;3244-3254.
11. Bross P.F., Beitz J., Chen G., Chen X.H., Duffy E., Kieffer L., Roy S., Sridhara R., Rahman A., Williams G., Pazdur R. Approval summary: Gemtuzumab Ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7:2001;1490-1496.
12. Baur M.P., Fimmers R., Fritsche C., Hummelink M., Neugebauer M., Acton R.T., Hodge T., Barbosa J., Bertrams J., Fehsel K. Genetic analysis of IDDM: the GAW5 multiplex family dataset. Genet. Epidemiol. 6:1980;15-20.
13. Zweerink H.J., Gammon M.C., Utz U., Sauma S.Y., Harrer T., Hawkins J.C., Johnson R.P., Sirotina A., Hermes J.D., Walker B.D. Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J. Immunol. 150:1993;1763-1771.
14. + T cell response to Epstein-Barr virus (EBV): implications for the pathogenesis of EBV-associated lymphoproliferative disorders. Blood. 91:1998;3875-3883.
15. Nijman H.W., Houbiers J.G., Vierboom M.P., van der Burg S.H., Drijfhout J.W., D'Amaro J., Kenemans P., Melief C.J., Kast W.M. Identification of peptide sequences that potentially triggers HLA-A2.1-restricted cytotoxic T lymphocytes. Eur. J. Immunol. 23:1993;1215-1219.
16. Romani N., Gruner S., Brang D., Kampgen E., Lenz A., Trockenbacher B., Konwalinka G., Fritsch P.O., Steinman R.M., Schuler G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:1994;83-89.
17. Bakker A.B., Marland G., Boor A.J., Figdor C.G. Generation of anti-melanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res. 55:1995;5330-5334.
18. Hinkel A., Tso C.L., Gitlitz B.J., Neagos N., Schmid I., Paik S.H., deKernion J., Figlin R., Belldegrun A. Immunomodulatory dendritic cells generated from non-fractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma. J. Immunother. 23:2002;83-93.
19. Lapointe R., Toso J.F., Butts C., Young H.A., Hwu P. Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes. Eur. J. Immunol. 30:2000;3291-3298.
20. Schuurhuis D.H., Laban S., Toes R.E., Ricciardi-Castagnoli P., Kleijmeer M.J., van der Voort E.I., Rea D., Offringa R., Geuze H.J., Melief C.J., Ossendorp F. Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J. Exp. Med. 192:2000;145-150.
21. Chen Z., Moyana T., Saxena A., Warrington R., Jia Z., Xiang J. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int. J. Cancer. 93:2001;539-548.
22. Morel Y., Truneh A., Sweet R.W., Olive D., Costello R.T. The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J. Immunol. 167:2001;2479-2486.
23. Altman J.D., Moss P.A., Goulder P.J., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., McMichael A.J., Davis M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94-96.
24. Ikeda H., Old L.J., Schreiber R.D. The roles of IFN-gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13:2002;95-109.
25. Beatty G.L., Paterson Y. Regulation of tumor growth by IFN-gamma in cancer immunotherapy. Immunol. Res. 24:2001;201-210.
26. + cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate. 36:1998;129-138.
27. + T cells and intratumoral lymphotactin transgene expression. Cancer Res. 62:2002;2043-2051.
28. Kircher B., Stevanovic S., Urbanek M., Mitterschiffthaler A., Rammensee H.G., Grunewald K., Gastl G., Nachbaur D. Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion. Br. J. Haematol. 117:2002;935-939.
29. Johnson C.S., Chang M.J., Thurlow S.M., Pourbohloul S.C., Furmanski P. Immunotherapeutic approaches to leukemia: the use of the Friend virus-induced erythroleukemic model system. Cancer Res. 50(17 Suppl.):1990;S5682-S5686.
30. Matis L.A., Shu S., Groves E.S., Zinn S., Chou T., Kruisbeek A.M., Rosenstein M., Rosenberg S.A. Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL 2 receptor expression. J. Immunol. 136:1986;3496-3501.
31. Gordon J., Holden H.T., Segal S., Feldman M. Anti-tumor immunity in B-lymphocyte-deprived mice. III. Immunity to primary Moloney Sarcoma virus-induced tumors. Int. J. Cancer. 29:1982;351-357.
32. Brichard V., Van Pel A., Wolfel T., Wolfel C., De Plaen E., Lethe B., Coulie P., Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178:1993;489-495.
33. Coulie P.G., Lehmann F., Lethe B., Herman J., Lurquin C., Andrawiss M., Boon T. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA. 92:1995;7976-7980.
34. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643-1647.
35. Allen P.M. Peptides in positive and negative selection: a delicate balance [comment]. Cell. 76:1994;593-596.
36. Lanzavecchia A. How can cryptic epitopes trigger autoimmunity? J. Exp. Med. 181:1995;1945-1948.
37. Moudgil K.D., Ametani A., Grewal I.S., Kumar V., Sercarz E.E. Processing of self-proteins and its impact on shaping the T cell repertoire, autoimmunity and immune regulation. Int. Rev. Immunol. 10:1993;365-377.
38. Molldrem J., Komanduri K., Wieder E. Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions. Curr. Opin. Hematol. 9:2002;503-508.
39. Roessig C., Scherer S.P., Baer A., Vormoor J., Rooney C.M., Brenner M.K., Juergens H. Targeting CD19 with genetically modified EBV-specific human T lymphocytes. Ann. Hematol. 81(Suppl 2):2002;S42-S43.
40. Voss R.H., Lotz C., Cellary A., Theobald M. Targeting p53, hdm2, and CD19: vaccination and immunologic strategies. Bone Marrow Transplant. 25(Suppl. 2):2002;S43-S45.
41. Dillman R.O. Monoclonal antibody therapy for lymphoma: an update. Cancer Pract. 9:2001;71-80.
42. + malignancy. Biol. Blood Marrow Transplant. 4:1998;75-83.
43. Amrolia P.J., Reid S.D., Gao L., Schultheis B., Dotti G., Brenner M.K., Melo J.V., Goldman J.M., Stauss H.J. Alloreactive cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood. 101:2003;1007-1014.
44. Pangalis G.A., Dimopoulou M.N., Angelopoulou M.K., Tsekouras C., Vassilakopoulos T.P., Vaiopoulos G., Siakantaris M.P. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med. Oncol. 18:2001;99-107.
45. Hale G., Zhang M.J., Bunjes D., Prentice H.G., Spence D., Horowitz M.M., Barrett A.J., Waldmann H. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood. 92:1998;4581-4590.
46. Azuma K., Shichijo S., Maeda Y., Nakatsura T., Nonaka Y., Fujii T., Koike K., Itoh K. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site. Cancer Res. 63:2003;854-858.
47. Chada S., Mhashilkar A., Roth J.A., Gabriolvich D. Development of vaccines against self-antigens: the p53 paradigm. Curr. Opin. Drug Discov. Dev. 6:2003;169-173.
48. Zwaveling S., Van der Burg S.H., Menon A.G., Melief C.J., Offringa R. Immunotherapy of cancer through targeting of the p53 tumor antigen. Arch. Immunol. Ther. Exp. 50:2002;297-305.
49. Knutson K.L., Disis M.L. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient. Hum. Immunol. 63:2002;547-557.
50. Scardino A., Gross D.A., Alves P., Schultze J.L., Graff-Dubois S., Faure O. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J. Immunol. 168:2002;5900-5906.
51. Tanaka H., Tsunoda T., Nukaya I., Sette A., Matsuda K., Umano Y., Yamaue H., Takesako K., Tanimura H. Mapping the HLA-A24-restricted T-cell epitope peptide from a tumor-associated antigen HER2/neu: possible immunotherapy for colorectal carcinomas. Br. J. Cancer. 84:2001;94-99.
52. Legrand O., Perrot J.Y., Baudard M., Cordier A., Lautier R., Simonin G., Zittoun R., Casadevall N., Marie J.P. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood. 96:2000;870-877.
53. Griffin J.D., Linch D., Sabbath K., Larcom P., Schlossman S.F. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leukemia Res. 8:1984;521-534.
54. Dinndorf P.A., Andrews R.G., Benjamin D., Ridgway D., Wolff L., Bernstein I.D. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood. 67:1986;1048-1053.
55. Andrews R.G., Singer J.W., Bernstein I.D. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J. Exp. Med. 169:1989;1721-1731.
56. Estery E. Therapeutic options for acute myelogenous leukemia. Cancer. 92:2001;1059-1073.
57. McGavin J., Spencer C. Gemtuzumab ozogamicin. Drugs. 61:2001;1317-1322.
58. Parkhurst M.R., Salgaller M.L., Southwood S., Robbins P.F., Sette A., Rosenberg S.A., Kawakami Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157:1996;2539-2548.
59. Ruppert J., Sidney J., Celis E., Kubo R., Grey H.M., Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell. 74:1993;929-937.
60. Valmori D., Pittet M., Rimoldi D., Lienard D., Dunbar R., Cerundolo V., Lejene F., Cerottini J., Romero P. An antigen-targeted approach to adoptive transfer therapy of cancer. Cancer Res. 59:1999;2167-2173.
61. Molldrem J., Lee P., Wang C., Champlin R., Davis M. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donor that selectively lyse chronic myelogenous leukemia. Cancer Res. 59:1999;2675-2681.
62. Clark R., Dodi A., Hill S., Lill J., Aubert G., Macintyre A., Rojas J., Bourdon A., Bonner P., Wang L., Christmas S., Travers P., Creaser C., Rees R., Madrigal A. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood. 98:2001;2887-2893.
63. Osada T., Nagawa H., Takahashi T., Tsuno N.H., Kitayama J., Shibata Y. Dendritic cells cultured in anti-CD40 antibody-immobilized plates elicit a highly efficient peptide-specific T-cell response. J. Immunother. 25:2002;176-184.
64. Jonuleit H., Giesecke-Tuettenberg A., Tuting T., Thurner-Schuler B., Stuge T.B., Paragnik L., Kandemir A., Lee P.P., Schuler G., Knop J., Enk A.H. A comparison of two types of dendritic cells as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer. 93:2001;243-251.
65. + T cells. J. Immunol. 165:2000;1182-1190.
66. + ALL-specific HLA-A24-restricted cytotoxic T lymphocytes using a synthetic 16-mer minor bcr-abl peptide. Leukemia Res. 27:2003;253-257.
67. Kono K., Takahashi A., Sugai H., Fujii H., Choudhury A.R., Kiessling R., Matsumoto Y. Dendritic cells pulsed with HER-2/neu-drived peptides can induce specific T-cell responses in patients with gastric cancer. Clin. Cancer Res. 8:2003;3394-3400.
68. Kleihauer A., Grigoleit U., Hebart H., Moris A., Brossart P., Muhm A., Stevanovic S., Rammensee H.G., Sinzger C., Riegler S., Jahn G., Kanz L., Einsele H. Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells. Br. J. Haematol. 113:2001;231-239.
69. Mutis T., Blokland E., Kester M., Schrama E., Goulmy E. Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation. Blood. 100:2002;547-552.
70. Moris A., Teichgraber V., Gauthier L., Buhring H.J., Rammersee H.G. Cutting edge: characterization of allorestricted and peptide-selective alloreactive T cells using HLA-tetramer selection. J. Immunol. 166:2001;4818-4821.
71. Waller E.K., Ernstoff M.S. Modulation of antitumor immune responses by hematopoietic cytokines. Cancer. 97:2003;1797-1809.
72. Galea-Lauri J., Darling D., Mufti G., Harrison P., Farzaneh F. Immunological weapons against acute myeloid leukemia. Immunology. 107:2002;20-27.
73. Braun S.W., Gerhartz H.H., Schmetzer H.M. Influence of cytokines and autologus lymphokine-activated killer cells on leukemic bone marrow cells and colonies in AML. Acta Haematol. 105:2001;209-221.
74. + haematopoietic progenitor cells. Br. J. Haematol. 84:1993;24-30.
75. Jilani I., Estey E., Huh Y., Joe Y., Manshouri T., Yared M., Giles F., Kantarjian H., Cortes J., Thomas D., Keating M., Freireich E., Albitar M. Differences in CD33 intensity between various myeloid neoplasms. Am. J. Clin. Pathol. 118:2002;560-566.
76. Gao Z., McAlister V.C., Williams G.M. Repopulation of liver endothelium by bone marrow derived cells. Lancet. 357:2001;932-933.
77. Chiriva-Internati M., Wang Z., Salati E., Wroblewski D., Lim S.H. Successful generation of sperm protein 17 (SP17) specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for SP17-positive multiple myeloma. Scand. J. Immunol. 56:2002;429-433.
78. Lum L.G., Lefever A.V., Treisman J.S., Garlie N.K., Hanson J.P. Jr. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial. J. Immunother. 24:2001;408-419.